Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor
The structure was published by Revesz, L., Schlapbach, A., Aichholz, R., et al., Scheufler, C., Velcicky, J., and Huppertz, C., in 2010 in a paper entitled "In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II." (abstract).
This crystal structure was determined using X-ray diffraction at a resolution of 2.41 Å and deposited in 2010.
The experimental data on which the structure is based was also deposited.
The PDB entry contains the structure of MAP kinase-activated protein kinase 2. This molecule has the UniProt identifier P49137 (MAPK2_HUMAN). The sample contained 299 residues which is < 90% of the natural sequence. Out of 299 residues 283 were observed and are deposited in the PDB.
It also contains one or more heterogenic compounds (e.g., ligands, co-factors, ions, modified amino acids, etc.); see here for a complete list.
The molecule is most likely monomeric.
The following tables show cross-reference information to other databases (to obtain a list of all PDB entries sharing the same property or classification, click on the magnifying glass icon):
This entry contains 1 unique UniProt protein: